Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants

Area of Science:

• Immunology
• Vaccinology
• Molecular Biology

Background:

• Developing effective vaccines requires adjuvants that induce robust T-cell responses.
• Cellular immunity is key for protection against intracellular pathogens and cancer.
• Cyclic dinucleotides (CDNs) are bacterial molecules that act as potent vaccine adjuvants.

Purpose of the Study:

• To explore the potential of cyclic dinucleotides (CDNs) as adjuvants for enhancing vaccine efficacy.
• To investigate the STING signaling pathway's role in CDN-mediated immune activation.
• To assess the applicability of CDNs in preventive vaccines and cancer immunotherapies.

Main Methods:

• Activation of the STING (stimulator of interferon genes) signaling pathway by CDNs.
• Induction of interferon-β (IFN-β) and NF-κB dependent inflammatory cytokines.
• Analysis of CDN-STING interactions and their implications for immune response.

Main Results:

• CDNs activate innate immunity via the STING pathway, independent of Toll-like receptors (TLRs).
• CDN-STING co-crystal structures provide insights into adjuvant mechanisms.
• CDN-STING pathway activation enhances immune responses, showing promise in preclinical models.

Conclusions:

• CDNs represent a promising new class of adjuvants for vaccines and immunotherapies.
• Further research and human trials are warranted to translate CDN-STING findings into clinical applications.
• The STING pathway is a critical target for modulating immune responses against pathogens and cancer.